JP2015520182A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520182A5 JP2015520182A5 JP2015515640A JP2015515640A JP2015520182A5 JP 2015520182 A5 JP2015520182 A5 JP 2015520182A5 JP 2015515640 A JP2015515640 A JP 2015515640A JP 2015515640 A JP2015515640 A JP 2015515640A JP 2015520182 A5 JP2015520182 A5 JP 2015520182A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- antibody
- fragment
- seq
- trka
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002193 Pain Diseases 0.000 claims 16
- 239000012634 fragment Substances 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 101150111783 NTRK1 gene Proteins 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 208000004454 Hyperalgesia Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 101000961149 Homo sapiens Immunoglobulin heavy constant gamma 4 Proteins 0.000 claims 2
- 208000035154 Hyperesthesia Diseases 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102100039347 Immunoglobulin heavy constant gamma 4 Human genes 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 206010053552 allodynia Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000010103 fibrous dysplasia Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 201000007094 prostatitis Diseases 0.000 claims 2
- 102220011641 rs201315884 Human genes 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000014181 Bronchial disease Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010062746 Carditis Diseases 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 208000029147 Collagen-vascular disease Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010011796 Cystitis interstitial Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010072132 Fracture pain Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000000913 Kidney Calculi Diseases 0.000 claims 1
- 206010024453 Ligament sprain Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000010040 Sprains and Strains Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 238000001516 cell proliferation assay Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000035874 hyperreactivity Effects 0.000 claims 1
- 208000021646 inflammation of heart layer Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000017445 musculoskeletal system disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000025661 ovarian cyst Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 108010067988 prolactin-binding protein Proteins 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 230000002889 sympathetic effect Effects 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 230000009092 tissue dysfunction Effects 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000001457 vasomotor Effects 0.000 claims 1
- 208000001319 vasomotor rhinitis Diseases 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657184P | 2012-06-08 | 2012-06-08 | |
| US61/657,184 | 2012-06-08 | ||
| PCT/IB2013/054688 WO2013183032A2 (en) | 2012-06-08 | 2013-06-07 | Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015520182A JP2015520182A (ja) | 2015-07-16 |
| JP2015520182A5 true JP2015520182A5 (enExample) | 2016-07-28 |
Family
ID=48906463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515640A Pending JP2015520182A (ja) | 2012-06-08 | 2013-06-07 | アミノ酸置換を有するヒト化抗ＴｒｋＡ抗体 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20130344064A1 (enExample) |
| EP (1) | EP2859019B1 (enExample) |
| JP (1) | JP2015520182A (enExample) |
| KR (1) | KR20150023679A (enExample) |
| CN (1) | CN104520330A (enExample) |
| AP (1) | AP2014008145A0 (enExample) |
| AU (1) | AU2013273115B2 (enExample) |
| CA (1) | CA2875703A1 (enExample) |
| CL (1) | CL2014003339A1 (enExample) |
| CO (1) | CO7240431A2 (enExample) |
| EA (1) | EA201492163A1 (enExample) |
| ES (1) | ES2666126T3 (enExample) |
| IL (1) | IL235994A0 (enExample) |
| IN (1) | IN2014MN02656A (enExample) |
| MX (1) | MX362394B (enExample) |
| PE (1) | PE20150212A1 (enExample) |
| PH (1) | PH12014502722A1 (enExample) |
| SG (1) | SG11201408037SA (enExample) |
| UA (1) | UA113879C2 (enExample) |
| WO (1) | WO2013183032A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| EP2646468B1 (en) | 2010-12-01 | 2018-07-25 | AlderBio Holdings LLC | Anti-ngf compositions and use thereof |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| MA41097A (fr) * | 2014-12-05 | 2017-10-10 | Glenmark Pharmaceuticals Sa | Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses |
| WO2016190263A1 (ja) | 2015-05-22 | 2016-12-01 | アステラス製薬株式会社 | 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント |
| MX2019008221A (es) * | 2017-01-10 | 2019-12-09 | Univ Yamaguchi | Anticuerpo anti-gpc3. |
| MY202872A (en) | 2017-11-20 | 2024-05-28 | Just Evotec Biologics Inc | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
| AR114110A1 (es) * | 2018-02-28 | 2020-07-22 | Lilly Co Eli | Anticuerpo anti-trka |
| EP3976657A4 (en) * | 2019-05-30 | 2023-07-05 | Sunshine Lake Pharma Co., Ltd. | ANTI-TRKA ANTIBODIES AND USES THEREOF |
| CN112625128B (zh) * | 2020-08-06 | 2022-11-08 | 熙源安健医药（上海）有限公司 | 抗ngf抗体及其抗原结合片段、其制备方法和应用 |
| JP7837873B2 (ja) * | 2020-11-20 | 2026-03-31 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | ヒト化抗ＴｒｋＡ抗体及びその使用 |
| CN112961244B (zh) | 2021-02-28 | 2023-08-29 | 熙源安健医药（上海）有限公司 | 抗TrkA抗体或其抗原结合片段、其制备方法和应用 |
| KR20260013489A (ko) * | 2023-05-23 | 2026-01-28 | 4비 테크놀로지스 (상하이) 컴퍼니 리미티드 | TrkA 항체 및 이의 용도 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
| US6548062B2 (en) | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| ES2694247T3 (es) * | 2005-05-20 | 2018-12-19 | Ablynx N.V. | NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación |
| ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| FI118245B (fi) | 2005-06-08 | 2007-08-31 | Iprbox Oy | Kamera |
| ITRM20050332A1 (it) | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
| ES2593484T3 (es) * | 2007-03-29 | 2016-12-09 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| EP2252633B9 (en) | 2008-02-04 | 2014-02-19 | Lay Line Genomics S.P.A. | Anti-trka antibodies and derivatives thereof |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2013
- 2013-06-07 ES ES13742750.6T patent/ES2666126T3/es active Active
- 2013-06-07 AP AP2014008145A patent/AP2014008145A0/xx unknown
- 2013-06-07 IN IN2656MUN2014 patent/IN2014MN02656A/en unknown
- 2013-06-07 SG SG11201408037SA patent/SG11201408037SA/en unknown
- 2013-06-07 MX MX2014015043A patent/MX362394B/es active IP Right Grant
- 2013-06-07 CN CN201380042359.9A patent/CN104520330A/zh active Pending
- 2013-06-07 KR KR20157000453A patent/KR20150023679A/ko not_active Ceased
- 2013-06-07 CA CA2875703A patent/CA2875703A1/en not_active Abandoned
- 2013-06-07 EP EP13742750.6A patent/EP2859019B1/en active Active
- 2013-06-07 EA EA201492163A patent/EA201492163A1/ru unknown
- 2013-06-07 WO PCT/IB2013/054688 patent/WO2013183032A2/en not_active Ceased
- 2013-06-07 JP JP2015515640A patent/JP2015520182A/ja active Pending
- 2013-06-07 AU AU2013273115A patent/AU2013273115B2/en not_active Ceased
- 2013-06-07 PE PE2014002388A patent/PE20150212A1/es not_active Application Discontinuation
- 2013-06-07 UA UAA201413515A patent/UA113879C2/uk unknown
- 2013-06-07 US US13/913,057 patent/US20130344064A1/en not_active Abandoned
-
2014
- 2014-11-30 IL IL235994A patent/IL235994A0/en unknown
- 2014-12-04 PH PH12014502722A patent/PH12014502722A1/en unknown
- 2014-12-05 CL CL2014003339A patent/CL2014003339A1/es unknown
- 2014-12-30 CO CO14285848A patent/CO7240431A2/es unknown
-
2016
- 2016-09-14 US US15/265,331 patent/US20170218087A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015520182A5 (enExample) | ||
| Lewis et al. | Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface | |
| AU2019205981B2 (en) | Multispecific antibody constructs | |
| HRP20211357T1 (hr) | Bispecifična protutijela specifična za pd-1 i tim3 | |
| US20130101586A1 (en) | Stable multiple antigen-binding antibody | |
| RU2013152164A (ru) | Анти-в7-н3-антитело | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| JP2008542440A5 (enExample) | ||
| US11834514B2 (en) | Method for increasing the percentage of monomeric antibody Fab-dsFv multimeric species | |
| EP3904381A1 (en) | Antibody fusion protein, preparation method therefor and application thereof | |
| RU2018135371A (ru) | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb | |
| ES3035839T3 (en) | Affinity engineered serum protein carrier binding domain | |
| US20240092897A1 (en) | Anti-siglec-15 antibody and application thereof in preparing drug | |
| US12570738B2 (en) | Multi-specific antibody with binding specificity for human IL-13 and IL-17 | |
| WO2020243489A1 (en) | IL-6Rα/IL-8R BISPECIFIC BINDING AGENTS FOR INHIBITING CANCER CELL MIGRATION | |
| JP2026510317A (ja) | 抗ｃｌｄｎ６及び抗ｃｄ３多重特異性抗体及び使用方法 | |
| NZ763877A (en) | Monoclonal antibody to il-5rα | |
| TW202436353A (zh) | 抗ｃｌｄｎ６與抗ｃｄ３多重特異性抗體以及使用方法 | |
| HK40069078A (en) | Multi-specific antibody with binding specificity for human il-13 and il-17 | |
| NZ745999B2 (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
| NZ744125B2 (en) | Bispecific t cell engaging antibody constructs | |
| NZ784569A (en) | Bispecific t cell engaging antibody constructs | |
| NZ728534B2 (en) | Bispecific antibodies against cd3epsilon and bcma | |
| NZ728534A (en) | Bispecific antibodies against cd3epsilon and bcma |